Emilie Branch, Scientific Content Manager, That's Nice LLC / Nice Insight03.01.17
Biopharmaceuticals may be surging, but small molecule, solid dose medications are far from on their way out. In 2015, over 50% of the 45 new molecular entities (NMEs) approved by the FDA were solid dose products—15 tablets, 8 capsules. Despite significant improvements in drug development, as well as groundbreaking discoveries in the larger pharmaceutical market, oral solid dose (OSD) remains both popular and effective, with the OSD manufacturing process largely the same as it has always been. That reality alone speaks volumes about solid dose, but it also means there is room for innovation. However, this innovation will involve more than manufacturing efficiencies and packaging solutions.
In the face of today’s large molecule drugs, the future of OSD will likely rely heavily on high-potency compounds, niche drug forms and generics. With that, it is likely that innovation will come in the areas of improved drug delivery, enhanced efficacy and, most importantly, a deeper understanding of patient needs and wants. This includes psychological associations related to a drug’s physical appearance. Manufacturing improvements will play an important role as 3
In the face of today’s large molecule drugs, the future of OSD will likely rely heavily on high-potency compounds, niche drug forms and generics. With that, it is likely that innovation will come in the areas of improved drug delivery, enhanced efficacy and, most importantly, a deeper understanding of patient needs and wants. This includes psychological associations related to a drug’s physical appearance. Manufacturing improvements will play an important role as 3
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
